Holen Sie sich die Stockscreener-App
5.70
2.12%
-0.21
Schlusskurs vom Vortag:
$5.91
Offen:
$5.91
24-Stunden-Volumen:
13,185
Relative Volume:
0.16
Marktkapitalisierung:
$72.33M
Einnahmen:
$4.28M
Nettoeinkommen (Verlust:
$-7.28M
KGV:
-6.9973
EPS:
-0.8146
Netto-Cashflow:
$-6.17M
1W Leistung:
-2.77%
1M Leistung:
-18.41%
6M Leistung:
+0.61%
1J Leistung:
+136.12%
1-Tages-Spanne:
$5.70
$5.91
1-Wochen-Bereich:
$5.70
$6.12
52-Wochen-Spanne:
$2.21
$9.33
Neuraxis Inc Stock (NRXS) Company Profile
Firmenname
Neuraxis Inc
Sektor
Branche
Telefon
(812) 689-0791
Adresse
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
5.76 | 74.22M | 4.28M | -7.28M | -6.17M | -0.8146 |
VRTX
Vertex Pharmaceuticals Inc
|
522.22 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.12 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
999.14 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
139.10 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.35 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neuraxis Inc Aktie (NRXS) Neueste Nachrichten
Neuraxis Inc. (NRXS) Peer Comparison – Compare with Others - Value Research
Neuraxis Inc. (NRXS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Neuraxis (NRXS) Q2 2026 Earnings: EPS Beats Its Estimate in the Latest Session; Price Move: Shares Finish 1.91% Down in the Current UpdateEarnings Expansion Phase - vinanet.vn
NeurAxis Earnings Call Signals High Growth, High Hurdles - TipRanks
NeurAxis Enhances Executive and Director Equity Compensation - TipRanks
Neuraxis (NRXS) grants CEO 199K instantly vesting stock units - Stock Titan
NeurAxis (NRXS) Institutional Ownership 2026 - MarketBeat
NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up - NewsBreak: Local News & Alerts
Neuraxis (NRXS) Q2 2026 Earnings: Narrower Loss Beats Estimates, Stock Jumps 32%Performance Review - vinanet.vn
NRXS Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 32% Stock SurgeEarnings Per Share - Vinanet
Neuraxis Inc. (NRXS) Q2 2026 Earnings: Narrower Loss Beats Expectations as Stock Holds SteadyStrong Earnings Momentum - vinanet.vn
NRXS Q2 2026 Earnings: 41.79% EPS Beat Signals Cost Discipline, Yet Shares Slip 1.26%Return On Assets - vinanet.vn
NeurAxis revenues up 116% to USD 1.9M in Q2 2026 - Medical Buyer
NeurAxis, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
NeurAxis (NRXS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Could NeurAxis (NASDAQ:NRXS) Reshape Nasdaq Composite Focus? - Kalkine Media
Transcript : NeurAxis, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
NeurAxis (NASDAQ:NRXS): What Could Today’s Update Reveal About Pediatric Therapy Adoption And Reimbursement? - Kalkine Media
NRXS: Q2 revenue up 116% YoY, gross margin at 85.9%, with payer coverage and VA expansion driving growth - TradingView
Earnings call transcript: NeurAxis falls on Q2 2026 EPS miss despite 116% revenue growth - Investing.com
NeurAxis reports 116% revenue growth in second quarter 2026 By Investing.com - Investing.com Nigeria
NeurAxis reports 116% revenue growth in second quarter 2026 - Investing.com
NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth - The Manila Times
NRXS: Q2 2026 revenue surged 116% year-over-year, with gross margin up to 85.9% and strong cash position - TradingView
NRXS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NeurAxis (NYSE American: NRXS) doubles sales yet warns on going concern - Stock Titan
Earnings To Watch: Neuraxis Inc (NRXS) Q2 2026 -- GF Value Sees 55% Downside - Yahoo Finance
NeurAxis, Inc. (NRXS) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
NeurAxis宣佈爲IB-Stim PENFS療法增加美國中大西洋地區的覆蓋範圍，將服務擴展至超過500,000人 - Moomoo
Neuraxis Expands Payer Coverage for Percutaneous Electrical Nerve Field Stimulation and Ib-Stim Treatment - marketscreener.com
NeurAxis expands insurance coverage for its IB-Stim neuromodulation device, adding 500,000 covered lives. - Pluang
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Neuraxis Q1 2026 Earnings: Narrower-Than-Expected Loss as EPS Beats Consensus by 7.12%Dividend Cut Risk - vinanet.vn
NRXS|Neuraxis Inc|Price:6.735|Chg%:+0.485 - TradingKey
Neuraxis Inc (NRXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NRXS Q1 2026 Earnings: Narrower-than-Expected Loss Despite Stock DeclineEPS Estimate Trend - vinanet.vn
NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026 - The Manila Times
NeurAxis, Inc. to Report Second Quarter 2026 Financial Results on August 11 and Host Conference Call - Quiver Quantitative
Neuraxis Inc (NRXS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuraxis Inc (NRXS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neuraxis Inc (NRXS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neuraxis Inc (NRXS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NRXS|Neuraxis Inc|Price:6.800| - TradingKey
Neuraxis Inc (NRXS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Neuraxis, Inc. Revenue Breakdown – AMEX:NRXS - TradingView
Form S-3 Neuraxis Inc For: 24 July By Investing.com - Investing.com South Africa
Neuraxis Inc. (NRXS) Posts Modest Gains, Testing Key LevelsValue Area High - Vinanet
NRXS Q1 2026 Earnings: EPS Beat as Narrower-Than-Expected Losses Offset by Stock DeclineEarnings Yield Analysis - vinanet.vn
NRXS Q1 2026 Earnings: Narrower Loss Surprises, but Stock Declines 2.87%Earnings Forecast Report - vinanet.vn
Neuraxis Inc. (NRXS) Q1 2026 Earnings: EPS Beat Despite Negative Bottom Line, Stock SlidesEarnings Season Preview - DonanımHaber
Finanzdaten der Neuraxis Inc-Aktie (NRXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
Kapitalisierung:
|
Volumen (24h):